-+ 0.00%
-+ 0.00%
-+ 0.00%

SUMMIT THERAPEUTICS - PHASE II STUDY EVALUATES IVONESCIMAB ALONE AND WITH CADONILIMAB OR IPILIMUMAB IN ADVANCED CCRCC

Reuters·10/19/2026 11:05:18